68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase II/III trial studies how well gallium (Ga) 68-labeled gastrin-releasing peptide
receptor (GRPR) antagonist BAY86-7548 (68Ga-RM2) positron emission tomography (PET)/magnetic
resonance imaging (MRI) works in detecting prostate cancer in patients with negative computed
tomography (CT) scan and elevated prostate-specific antigen levels after treatment with
surgery or radiation. PET/MRI scans take both PET and MRI images at the same time and combine
them into a single picture and is used to describe information regarding the function, as
well as location and size of a tumor. 68Ga-RM2, a compound made of a radioactive agent linked
to a pharmacological substance that is strongly attracted by a substance made by tumor cells,
to detect prostate cancer. 68Ga-RM2 PET/MRI may be able to see smaller tumors than the
standard of care contrast-enhanced CT or MRI scan